D-048
N-去甲基氯氮平标准液 CRM 溶液
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H17ClN4
化学文摘社编号:
分子量:
312.80
UNSPSC Code:
41116107
MDL number:
NACRES:
NA.24
EC Number:
200-659-6
产品名称
N-去甲基氯氮平标准液 CRM 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
InChI key
JNNOSTQEZICQQP-UHFFFAOYSA-N
InChI
1S/C17H17ClN4/c18-12-5-6-15-16(11-12)21-17(22-9-7-19-8-10-22)13-3-1-2-4-14(13)20-15/h1-6,11,19-20H,7-10H2
SMILES string
Clc1ccc2Nc3ccccc3C(=Nc2c1)N4CCNCC4
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
shipped in
wet ice
storage temp.
−20°C
Quality Level
General description
N-去甲基氯氮平是氯氮平的活性代谢物，而后者是治疗精神分裂症的非典型抗精神病药物。氯氮平在美国以Clozaril和FrazaClo®商品名出售。此款Snap-N-Spike®溶液经过认证，适用于尿液药物检测、临床毒理学、法医分析以及LC-MS/MS或GC/MS法临床监测。
Other Notes
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Jelveh Lameh et al.
Pharmacology & therapeutics, 115(2), 223-231 (2007-06-23)
Currently available treatments for schizophrenia have limited efficacy and are generally poorly tolerated. However, among these antipsychotic agents, clozapine stands apart in having generally superior motoric tolerability and efficacy. One intriguing possibility, based on clinical correlations, receptor activity profiles and
Tania Godoy et al.
European journal of oral sciences, 119(4), 275-281 (2011-07-06)
Many drugs (e.g. amisulpride) have been used to treat troublesome clozapine-induced salivation; however, varying success has been achieved in this respect, probably because, until recently, the salivatory action of clozapine has been largely unexplained. In the rat, clozapine and its
Thomas I F H Cremers et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(10), 1909-1916 (2012-06-28)
A significant barrier to realization of the full potential of clozapine as a therapeutic agent in the treatment of schizophrenia is the substantial interpatient variability that exists along the therapeutic continuum of no response-efficacious response-adverse response. Genetic polymorphisms that manifest
R J Flanagan et al.
Forensic science international, 206(1-3), e31-e36 (2010-08-20)
To highlight some problems that may occur when investigating clozapine-associated deaths including (i) that death may be related to gastrointestinal hypomotility and (ii) that post-mortem blood clozapine and norclozapine concentrations may not reflect ante-mortem concentrations. A 41-year-old male died 40
Yousheng Cai et al.
Scientific reports, 10(1), 10444-10444 (2020-06-28)
Parkinson's disease (PD) is a common dyskinesia disease, the mitochondrial unfolded protein response (mtUPR) may be directly or indirectly involved in the occurrence and development of PD, although the exact mechanism is unclear. We established a dopaminergic neuronal-like cell model
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持